ATOS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases...

Stats
Today's Volume	852 744
Average Volume	1.69M
Market Cap	190.46M
EPS	$0 ( 2024-04-03 )
Next earnings date	( $-0.0700 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.33
ATR14	$0.00400 (0.26%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-10	Finn Jonathan	Buy	25 000	Common Stock
2024-03-09	Cigler Tessa	Buy	20 834	Stock Option (right to buy)
2024-03-09	Cigler Tessa	Buy	0
2023-11-15	Weaver Gregory L	Sell	50 000	Common Stock
2023-11-15	Finn Jonathan	Buy	62 500	Stock Option (right to buy)

INSIDER POWER
71.55
Last 98 transactions
Buy: 26 594 652 \| Sell: 4 017 362

Volume Correlation

Long: 0.03 (neutral)

Short: 0.67 (moderate)

Signal:(56.239) Neutral

Atossa Therapeutics Inc Correlation

10 Most Positive Correlations
SVAC	0.927
MEDS	0.901
TLGT	0.888
PAIC	0.879
DMAC	0.867
STCN	0.863
SGH	0.861
LFMDP	0.86
XBIT	0.86
APYX	0.859

10 Most Negative Correlations
AMRB	-0.937
NETE	-0.916
LWAC	-0.884
MMAC	-0.883
SRAC	-0.882
LMRKN	-0.832
ENOB	-0.823
RAVN	-0.821
PAYS	-0.819
BLTE	-0.817

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Atossa Therapeutics Inc Correlation - Currency/Commodity

-0.47
( neutral )

-0.51
( weak negative )

0.00
( neutral )

-0.61
( weak negative )

Atossa Therapeutics Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-23 000.00 (0.00 %)
EPS:	$-0.240

Q4	2023
Revenue:	$0
Gross Profit:	$-14 000.00 (0.00 %)
EPS:	$-0.0619

Q3	2023
Revenue:	$0
Gross Profit:	$-3 000.00 (0.00 %)
EPS:	$-0.0495

Q2	2023
Revenue:	$0
Gross Profit:	$-3 000.00 (0.00 %)
EPS:	$-0.0776

Financial Reports:

No articles found.

Atossa Therapeutics Inc

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.